Autolus says FDA grants RMAT designation for obe-cel in lupus, lupus nephritis
AUTL•Phase 2 LUMINA study continues
The pivotal Phase 2 LUMINA study in refractory lupus nephritis continues enrolling, with data expected in 2028.
FDA grants RMAT designation for obe-cel
Autolus says the FDA has granted RMAT designation for Autolus’ obe-cel in systemic lupus erythematosus, including lupus nephritis.
The designation supports accelerated development and regulatory review for the cell therapy in serious disease.
